Navigation Links
BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis
Date:7/3/2009

TURKU, Finland, July 3 /PRNewswire/ -- BioCis Pharma Ltd., a privately held drug development company with its headquarters in Turku, Finland, announced positive results from its Phase IIa clinical trial of ProtoCure(TM) emulsion cream, the company's novel topical drug for dermatology. This double-blind, placebo-controlled study, conducted in Finland, included 13 patients with mild to moderate atopic dermatitis who applied the ProtoCure emulsion cream to the affected skin areas twice daily for up to four weeks. The objectives were to evaluate the tolerability, pharmacokinetics, and efficacy of the topical treatment.

Study results showed excellent safety profile, and no serious adverse events were reported during the study. No patient dropped out due to adverse side effects of the treatment. Pharmacokinetic analyses showed no systemic exposure to the active ingredient of the product. Efficacy was assessed by performing instrumental measurements of skin lesion redness (erythema) and skin barrier function by trans-epidermal water loss (TEWL) during the 28-day period. Physician assessments, such as Eczema Area and Severity Index (EASI) were also evaluated. ProtoCure emulsion cream was superior to placebo in decreasing skin redness and improving skin barrier function. Statistically significant improvement was observed as early as day 10 after begining treatment. There was also a significant improvement in EASI score over the whole treatment period for ProtoCure emulsion cream as a sign of positive treatment effect. The EASI score difference did not reach statistical significance when compared to placebo, mainly due to the small number of patients studied.

"We are very pleased with the promising results of this study," says Lasse Leino, CEO of BioCis Pharma. "Skin barrier dysfunction is now recognized as a hallmark feature of atopic dermatitis. Any drug showing capacity for restoring this disturbance has significant potential in atopic dermatitis therapy. Based on our results, ProtoCure(TM) emulsion cream holds great promises in the treatment of inflammatory skin disorders."

Atopic dermatitis is a chronic inflammatory disease of the skin with an onset typically already in infancy. It affects up to 20 per cent of the general population in the Western countries, and the prevalence rate is rising. Atopic dermatitis may significantly impair the quality of life of those affected. Existing treatments often have undesirable side effects and do not always meet the needs of patients.

BioCis Pharma Ltd. is a Karolinska Development portfolio company.

BioCis Pharma Ltd is an innovative drug development company developing drug therapies based on a novel, patented therapeutic principles that target unmet medical needs in substantial therapeutic markets including inflammation, allergy, and cancer. The company's main investors are Karolinska Development AB (publ.), Finnish Industry Investment Ltd., and Etra Invest Ltd.

http://www.biocis.com

Contacts: Dr. Lasse Leino, CEO, BioCis Pharma Ltd., mobile phone +358-40-849-4694, lasse.leino@biocis.com


'/>"/>
SOURCE BioCis Pharma Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
2. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
3. King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
4. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
5. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
6. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
7. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
8. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
9. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
10. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
11. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... York , April 27, 2016 ... report titled, "Skincare Devices Market - Global Industry Analysis, ... According to the report, the global skincare devices market ... is anticipated to expand at a CAGR of 10.1% ... in 2023. Browse the full Skincare Devices Market ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Coast Dental Fort Stewart ... at its new location in the Exchange Furniture Mall at 112 Vilseck Road in ... 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet general dentists ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Wharton ... $30,000 Perlman Grand Prize of the 2016 Wharton Business Plan Competition —as ... People’s Choice Award, and the Committee Award for Most ‘Wow Factor,’ making them ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
Breaking Medicine News(10 mins):